NCT03904082

Brief Summary

To evaluate the ability of Erector spina Plane block and Serratus Anterior Plane block to decrease postoperative pain and analgesia requirements in patients undergoing thoracotomy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
105

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2019

Completed
9 days until next milestone

Study Start

First participant enrolled

April 1, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 4, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
Last Updated

April 8, 2019

Status Verified

April 1, 2019

Enrollment Period

9 months

First QC Date

March 23, 2019

Last Update Submit

April 4, 2019

Conditions

Keywords

dispne, pain

Outcome Measures

Primary Outcomes (2)

  • opioid consumption

    In the recovery room, all patients will given a patient- controlled analgesia device containing morphine 0.5 mg/ml, set to deliver a 1mg bolus dose of morphine with an 15 min lockout time and 6 mg 1 h limit.Total morphine consumption during the 48 hours postoperative period will recorded at 6 time intervals ( 2, 4, 6, 12, 24, 48. hours).

    48 hours after surgery

  • Verbal analog Pain Scores on rest and movement

    A Research assistant, blinded to the group allocation, interviewed patients and collected data at 6 time intervals ( 2, 4, 6, 12, 24, 48. hours) in the 48 hours postoperatively. Patients were asked to rate their pain using verbal analog scale, where 0= no pain and 10= worst pain possible.

    48 hours after surgery

Secondary Outcomes (1)

  • Incidences of adverse effects (like nausea and vomitting)

    48 hours after surgery

Study Arms (3)

Erector spinae plane block group (ESP)

ACTIVE COMPARATOR

Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4 vertebral level will performed preoperatively to patients in the ESP group (Group I).

Procedure: Erector Spinae Plane block ( Group ı)

Serratus Anterior Plane Block Group (SAP)

ACTIVE COMPARATOR

Single- shot ultrasound (Esaote Mylab30 )guided SAP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) the T4 vertebral level will performed preoperatively to patients in the SAP group( Group II).

Procedure: Serratus Anterior Plane block ( Group ıı)

Control Group

PLACEBO COMPARATOR

The Control group receive no intervetion ( Group III).

Procedure: Control Group (GROUPIII)

Interventions

ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Erector spinae plane block group (ESP)

SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Serratus Anterior Plane Block Group (SAP)

Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Control Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA I- ASA II Patients

You may not qualify if:

  • history of allergy to the study medication
  • refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ayşe Ülgey

Kayseri, Talas, 38100, Turkey (Türkiye)

Location

Related Publications (3)

  • Gurkan Y, Aksu C, Kus A, Yorukoglu UH, Kilic CT. Ultrasound guided erector spinae plane block reduces postoperative opioid consumption following breast surgery: A randomized controlled study. J Clin Anesth. 2018 Nov;50:65-68. doi: 10.1016/j.jclinane.2018.06.033. Epub 2018 Jul 2.

    PMID: 29980005BACKGROUND
  • Chin KJ, Adhikary S, Sarwani N, Forero M. The analgesic efficacy of pre-operative bilateral erector spinae plane (ESP) blocks in patients having ventral hernia repair. Anaesthesia. 2017 Apr;72(4):452-460. doi: 10.1111/anae.13814. Epub 2017 Feb 11.

    PMID: 28188621BACKGROUND
  • Tulgar S, Senturk O. Ultrasound guided Erector Spinae Plane block at L-4 transverse process level provides effective postoperative analgesia for total hip arthroplasty. J Clin Anesth. 2018 Feb;44:68. doi: 10.1016/j.jclinane.2017.11.006. Epub 2017 Nov 14. No abstract available.

    PMID: 29149734BACKGROUND

MeSH Terms

Conditions

Thoracic DiseasesPain

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Respiratory Tract DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Ayşe Ülgey, MD

    TC Erciyes University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associated professor

Study Record Dates

First Submitted

March 23, 2019

First Posted

April 4, 2019

Study Start

April 1, 2019

Primary Completion

January 1, 2020

Study Completion

January 1, 2020

Last Updated

April 8, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will share

De-identifed individual participant data for all primary and secondary outcome measures will be made aailable.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Data will be aailable within 10 months of study completion.
Access Criteria
Data accep requests will be rewiewed by an external independent Review Panel.Requesters will be required to sign a Data Access Agreement.

Available IPD Datasets

Clinical Study Report Access

Locations